Genetics can change dementia risk, but it usually does not determine whether someone will develop Alzheimer's disease. The main exceptions are rare inherited mutations that cause dominantly inherited Alzheimer's, while genetic testing is usually reserved for selected clinical situations. For families planning care in September 2026, the practical question is not simply "Is dementia genetic?" It is whether a result would clarify diagnosis, guide treatment, or help relatives make informed decisions.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does APOE testing actually tell you?
- When can a gene virtually determine Alzheimer's disease?
- Who should consider dementia genetic testing?
- How does frontotemporal dementia differ?
- When does APOE testing matter for treatment?
What does APOE testing actually tell you?
APOE is a gene involved in Alzheimer's risk. The APOE ε4 variant can raise risk and may be linked with an earlier onset, but some carriers never develop Alzheimer's, and some people without ε4 do. That makes APOE a risk factor, not a diagnosis. A consumer test showing ε4 cannot tell you whether you have Alzheimer's or provide a complete estimate of your overall risk.
The FDA advises discussing direct-to-consumer results with a qualified clinician or genetic counselor. The FDA's Direct-to-Consumer Tests guidance explains this limitation. Risk estimates also do not apply equally to every population. Genetic ancestry can affect the strength of APOE and other variant associations, which limits how precisely an individual result predicts the future. The National Institute on Aging's Alzheimer's disease Genetics Fact Sheet identifies this as an important limitation.
When can a gene virtually determine Alzheimer's disease?
Rare mutations in APP, PSEN1, or PSEN2 can cause dominantly inherited Alzheimer's disease. These conditions often produce symptoms before age 65, and a person who inherits one of these mutations is virtually certain to develop the disease during a normal lifespan. This pattern differs sharply from APOE-related risk.
A strong family history of dementia does not by itself prove that one of these mutations is present, but it can make specialist evaluation appropriate. Families may consider testing when several relatives developed Alzheimer's unusually early or when the inheritance pattern raises concern. Testing should begin with a clinician who can assess the family history and arrange genetic counseling.
Who should consider dementia genetic testing?
Clinicians do not routinely use genetic tests to diagnose or predict Alzheimer's disease or related dementias. A neurologist may order testing when someone has early symptoms and a strong family history of Alzheimer's disease or frontotemporal dementia. The National Institute on Aging's biomarker guidance describes this limited clinical role.
Before testing, ask what decision the result could change. Useful questions include: Genetic counseling should accompany clinically indicated testing. Counseling addresses potential benefits, risks, and limitations before testing and when results are returned, rather than leaving a family to interpret a difficult result alone.
- Would the result clarify the diagnosis?
- Could it affect treatment or eligibility discussions?
- What would a positive, negative, or uncertain result mean for relatives?
- Who will explain the result and document its limits?
How does frontotemporal dementia differ?
About one-third of frontotemporal dementia cases are inherited. Major genetic causes include changes in C9ORF72, MAPT, or GRN, but relatives can have very different ages of onset and symptoms. The National Institute on Aging's Frontotemporal Disorders resource notes this variation.
That variability matters for family conversations. One relative's age at onset cannot reliably predict another relative's timing or symptoms, even when a familial cause is present. When frontotemporal dementia appears repeatedly in a family, record diagnoses, approximate ages at symptom onset, and major symptoms. Bring that history to a neurologist or genetic counselor before deciding whether testing is useful.
When does APOE testing matter for treatment?
APOE ε4 testing can be clinically relevant for eligible people with amyloid-confirmed mild cognitive impairment or mild Alzheimer's dementia who are considering lecanemab or donanemab. ε4 homozygotes have a higher risk of ARIA, a treatment-related pattern of brain swelling or bleeding.
The FDA prescribing information for LEQEMBI and KISUNLA says APOE testing should occur before treatment. In this setting, the result helps discuss treatment risk; it does not diagnose Alzheimer's or predict the entire course of the disease.
